CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kruchko, 2018, The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone, Neuro Oncol., 20, 295, 10.1093/neuonc/noy006
Louis, 2007, WHO Classification of Tumours of the Central Nervous System
Ostrom, 2014, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011, Neuro. Oncol., 16, iv1, 10.1093/neuonc/nou223
Centers for Disease Control and Prevention (CDC). National Program of Cancer Registries Cancer Surveillance System Rationale and Approach. 1999; http://www.cdc.gov/cancer/npcr/pdf/npcr_css.pdf. Accessed September 24, 2019.
Wiśniewski, 2009, Universal sample preparation method for proteome analysis, Nat Methods., 6, 359, 10.1038/nmeth.1322
2002, Benign Brain Tumor Cancer Registries Amendment Act, 107th Cong
National Cancer Institute. Overview of the SEER Program. http://seer.cancer.gov/about/overview.html. Accessed September 24, 2019.
Wöhrer, 2009, The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry, J Neurooncol., 95, 401, 10.1007/s11060-009-9938-9
Asklund, 2015, Brain tumors in Sweden: data from a population-based registry 1999–2012, Acta Oncol., 54, 377, 10.3109/0284186X.2014.975369
Centers for Disease Control and Prevention National Center for Health Statistics, 2019, National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database: U.S. Cancer Statistics Incidence Analytic Database – 1998–2016
Fritz, 2000, International Classification of Diseases for Oncology, 3
Surveillance Epidemiology and End Results (SEER) Program.
McCarthy, 2002, Consensus Conference on Brain Tumor Definition for registration. November 10, 2000, Neuro Oncol., 4, 134, 10.1215/15228517-4-2-134
Surveillance Research Program - National Cancer Institute. ICCC Recode ICD-O-3/WHO. 2008. http://seer.cancer.gov/iccc/iccc-who2008.html. Accessed September 24, 2019.
Steliarova-Foucher, 2005, International classification of childhood cancer, third edition, Cancer., 103, 1457, 10.1002/cncr.20910
Swerdlow, 2007, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed
Kleihues, 2000, Tumours of the Nervous System: World Health Organization Classification of Tumours
Louis, 2016, WHO Classification of Tumours of the Central Nervous System
American Joint Committee on Cancer. Collaborative Stage Data Collection System. 2015. http://www.cancerstaging.org/cstage/. Accessed September 24, 2019.
Lym, 2015, Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004–2011, J. Neurooncol., 10.1007/s11060-015-1775-4
Surveillance Research Program - National Cancer Institute. ICD-0–3 SEER Site/Histology Validation List. 2019. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=2ahUKEwiYh_zy6-nkAhXKl54KHb8RBmcQFjABegQIABAC&url=https%3A%2F%2Fseer.cancer.gov%2Ficd-o-3%2Fsitetype.icdo3.20190618.pdf&usg=AOvVaw2ajRWYKzw4HwVL1yj0j6KV. Accessed September 24, 2019.
R Core Team. R: A language and environment for statistical computing. 2019. http://www.R-project.org/. Accessed September 24, 2019.
Surveillance Epidemiology and End Results (SEER) Program, 2019
Wickham H . ggplot2: elegant graphics for data analysis. 2019. https://ggplot2.tidyverse.org/. Accessed September 24, 2019
Bivand R , RundelC. rgeos: Interface to Geometry Engine - Open Source (GEOS). R package version 0.5–11. 2019. http://CRAN.R-project.org/package=rgeos. Accessed September 24, 2019.
Bivand R , KeittT, RowlingsonB. rgdal: Bindings for the Geospatial Data Abstraction Library. R package version 1.4–4. 2019. http://CRAN.R-project.org/package=rgdal. Accessed September 24, 2019.
Luo J . SEER2R: reading and writing SEER*STAT data files. R package version 1.0. 2012. http://CRAN.R-project.org/package=SEER2R. Accessed September 24, 2019.
Bivand R , Lewin-KohN. maptools: Tools for Reading and Handling Spatial Objects. R package version 0.8–36. 2015. http://CRAN.R-project.org/package=maptools. Accessed September 24, 2019.
Gohel, 2019
Gohel, 2019
Bache, 2014
Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Populations - Total U.S. (1990–2017) - Linked To County Attributes - Total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released December 2018. http://seer.cancer.gov/popdata/.
Tiwari, 2006, Efficient interval estimation for age-adjusted cancer rates, Stat Methods Med Res., 15, 547, 10.1177/0962280206070621
NAACCR Race and Ethnicity Work Group, 2011, NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]. Springfield, IL: North American Association of Central Cancer Registries. September
United States Department of Agriculture, 2013
2019, Joinpoint Regression Program, Version 4.7.0.0
Kim, 2000, Permutation tests for joinpoint regression with applications to cancer rates, Stat Med., 19, 335, 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z
Zhu, 2012, Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence, Cancer., 118, 1100, 10.1002/cncr.27405
Edwards, 2014, Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, Cancer., 120, 1290, 10.1002/cncr.28509
Zullig, 2012, Cancer incidence among patients of the U.S. Veterans Affairs Health Care System, Mil Med., 177, 693, 10.7205/MILMED-D-11-00434
Clegg, 2002, Impact of reporting delay and reporting error on cancer incidence rates and trends, J. Natl. Cancer Inst., 94, 1537, 10.1093/jnci/94.20.1537
Midthune, 2005, Modeling reporting delays and reporting corrections in cancer registry data, J Am Stat Assoc., 100, 61, 10.1198/016214504000001899
Surveillance Epidemiology and End Results (SEER) Program. Cancer Incidence Rates Adjusted for Reporting Delay. 2016. http://surveillance.cancer.gov/delay/. Accessed September 24, 2019.
Li, 2016, Are benign and borderline brain tumors underreported?, J Registry Manag., 43, 187
Anderson, 1998, Report of the second workshop on age adjustment, Vital Health Stat 4., I
Anderson, 1998, Age standardization of death rates: implementation of the year 2000 standard, Natl Vital Stat Rep., 47, 1
Dickie, 2018, Solid Tumor Rules
Johnson, 2007, The 2007 Multiple Primary and Histology Coding Rules
Ostrom, 2015, Alex’s Lemonade Stand Foundation Infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011, Neuro Oncol., 16, x1, 10.1093/neuonc/nou327
de Blank, 2015, Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009, Cancer Med., 4, 608, 10.1002/cam4.410
National Cancer Institute at the National Institutes of Health. Adolescents and Young Adults with Cancer. http://www.cancer.gov/cancertopics/aya. Accessed September 24, 2019.
Ostrom, , American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012, Neuro Oncol., 18, i1, 10.1093/neuonc/nov297
McCarthy, 2013, The impact of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107–260) on non-malignant brain and central nervous system tumor incidence trends, J Registry Manag., 40, 32
Gittleman, 2015, Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010, Cancer., 121, 102, 10.1002/cncr.29015
Kshettry, 2015, Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States, Neuro Oncol., 17, 1166, 10.1093/neuonc/nov069
Zhang, 2016, Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010, Neuro Oncol., 10.1093/neuonc/now252
Gittleman, 2018, Survivorship in adults with malignant brain and other central nervous system tumor from 2000–2014, Neuro Oncol., 10.1093/neuonc/noy090
Rouse, 2016, Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010, Neuro Oncol., 18, 70, 10.1093/neuonc/nov249
2007, DevCan: Probability of Developing or Dying of Cancer Software, Version 6.2.0
Fay, 2003, Age-conditional probabilities of developing cancer, Stat Med., 22, 1837, 10.1002/sim.1428
Fay, 2004, Estimating age conditional probability of developing disease from surveillance data, Popul Health Metr., 2, 6, 10.1186/1478-7954-2-6
Surveillance Epidemiology and End Results (SEER) Program, 2019, DevCan database: “SEER 18 Incidence and Mortality, 2000–2016, with Kaposi Sarcoma and Mesothelioma”
Braganza, 2012, Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review, Neuro Oncol., 14, 1316, 10.1093/neuonc/nos208
Amirian, 2016, Approaching a scientific consensus on the association between allergies and glioma risk: a report from the glioma international case-control study, Cancer Epidemiol Biomarkers Prev., 25, 282, 10.1158/1055-9965.EPI-15-0847
Malmer, 2003, Familial brain tumours—genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients, Int J Cancer., 106, 260, 10.1002/ijc.11213
Wrensch, 1997, Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls, Am J Epidemiol., 145, 581, 10.1093/oxfordjournals.aje.a009154
Malmer, 1999, Familial aggregation of astrocytoma in northern Sweden: an epidemiological cohort study, Int J Cancer., 81, 366, 10.1002/(SICI)1097-0215(19990505)81:3<366::AID-IJC9>3.0.CO;2-0
Hill, 2003, Cancer in first-degree relatives and risk of glioma in adults, Cancer Epidemiol Biomarkers Prev., 12, 1443
Scheurer, 2007, Aggregation of cancer in first-degree relatives of patients with glioma, Cancer Epidemiol Biomarkers Prev., 16, 2491, 10.1158/1055-9965.EPI-07-0576
Ostrom, 2014, The epidemiology of glioma in adults: a “state of the science” review, Neuro Oncol., 16, 896, 10.1093/neuonc/nou087
Johnson, 2014, Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review, Cancer Epidemiol Biomarkers Prev., 23, 2716, 10.1158/1055-9965.EPI-14-0207
Wiemels, 2010, Epidemiology and etiology of meningioma, J Neurooncol., 99, 307, 10.1007/s11060-010-0386-3
Ostrom, 2019, Risk factors for childhood and adult primary brain tumors, Neuro Oncol., 10.1093/neuonc/noz123
Scheie, 2019, Biomarkers in tumors of the central nervous system - a review, APMIS., 127, 265, 10.1111/apm.12916
Velazquez Vega, 2018, Incorporating advances in molecular pathology into brain tumor diagnostics, Adv Anat Pathol., 25, 143, 10.1097/PAP.0000000000000186
Guerreiro Stucklin, 2018, Review of molecular classification and treatment implications of pediatric brain tumors, Curr Opin Pediatr., 30, 3, 10.1097/MOP.0000000000000562
Cairncross, 1998, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst., 90, 1473, 10.1093/jnci/90.19.1473
Vogelbaum, 2015, Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131, J Neurooncol., 124, 413, 10.1007/s11060-015-1845-7
van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol., 31, 344, 10.1200/JCO.2012.43.2229
The Cancer Genome Atlas Research Network, 2015, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas, N Engl J Med., 372, 2481, 10.1056/NEJMoa1402121
Ceccarelli, 2016, Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma, Cell., 164, 550, 10.1016/j.cell.2015.12.028
Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med., 352, 997, 10.1056/NEJMoa043331
Stupp, 2007, Chemoradiotherapy in malignant glioma: standard of care and future directions, J Clin Oncol., 25, 4127, 10.1200/JCO.2007.11.8554
Hegi, 2008, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol., 26, 4189, 10.1200/JCO.2007.11.5964
Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell., 17, 510, 10.1016/j.ccr.2010.03.017
Kool, 2012, Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas, Acta Neuropathol., 123, 473, 10.1007/s00401-012-0958-8
Northcott, 2012, Molecular subgroups of medulloblastoma, Expert Rev Neurother., 12, 871, 10.1586/ern.12.66
Northcott, 2012, Medulloblastomics: the end of the beginning, Nat Rev Cancer., 12, 818, 10.1038/nrc3410
Northcott, 2017, The whole-genome landscape of medulloblastoma subtypes, Nature., 547, 311, 10.1038/nature22973
Reifenberger, 2017, Advances in the molecular genetics of gliomas - implications for classification and therapy, Nat Rev Clin Oncol., 14, 434, 10.1038/nrclinonc.2016.204
Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol, 31, 337, 10.1200/JCO.2012.43.2674
Qi, 2014, Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms, Oncol Lett., 7, 1895, 10.3892/ol.2014.2013
Paldor, 2016, Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors, J Clin Neurosci., 34, 128, 10.1016/j.jocn.2016.05.017
van den Bent, 2013, MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951, Clin. Cancer Res., 19, 5513, 10.1158/1078-0432.CCR-13-1157
Jones, 2014, Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma, Nat Rev.Cancer., 14, 10.1038/nrc3811
Wu, 2014, The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma, Nat Genet., 46, 444, 10.1038/ng.2938
Mackay, 2017, Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma, Cancer Cell., 32, 520, 10.1016/j.ccell.2017.08.017
Hoffman, 2016, Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics, Acta Neuropathol Commun., 4, 1, 10.1186/s40478-015-0269-0
Grill, 2012, Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma, Pediatr Blood Cancer., 58, 489, 10.1002/pbc.24060
Lapin, 2017, Genomic insights into diffuse intrinsic pontine glioma, Front Oncol., 7, 10.3389/fonc.2017.00057
Ostrom, 2016, Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying), J Neurooncol., 130, 31, 10.1007/s11060-016-2217-7
Weir, 2014, Evaluation of North American Association of Central Cancer Registries’ (NAACCR) data for use in population-based cancer survival studies, J Natl Cancer Inst Monogr., 2014, 198, 10.1093/jncimonographs/lgu018
Wilson, 2014, Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995–2008, J Registry Manag., 41, 65
Kleihues, 1993, The new WHO classification of brain tumours, Brain Pathol., 3, 255, 10.1111/j.1750-3639.1993.tb00752.x
van den Bent, 2010, Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective, Acta Neuropathol., 120, 297, 10.1007/s00401-010-0725-7
Aldape, 2000, Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study, Cancer., 88, 2342, 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X
Sahm, 2014, Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma, Acta Neuropathol., 128, 551, 10.1007/s00401-014-1326-7
Jiao, 2012, Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas, Oncotarget., 3, 709, 10.18632/oncotarget.588
Wiestler, 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis, Acta Neuropathol., 126, 443, 10.1007/s00401-013-1156-z
Maire, 2014, Molecular pathologic diagnosis of epidermal growth factor receptor, Neuro Oncol., 16, viii1, 10.1093/neuonc/nou294
Arita, 2013, Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss, Acta Neuropathol., 126, 267, 10.1007/s00401-013-1141-6
Eckel-Passow, 2015, Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors, N Engl J Med., 372, 2499, 10.1056/NEJMoa1407279
Hawkins, 2011, BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma, Clin Cancer Res., 17, 4790, 10.1158/1078-0432.CCR-11-0034
Ceccom, 2014, Embryonal tumor with multilayered rosettes: diagnostic tools update and review of the literature, Clin Neuropathol., 33, 15, 10.5414/NP300636